Navigation Links
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Date:9/18/2007

HONOLULU, Sept. 18 Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center.

Susan Greenspan, M.D., director of the Osteoporosis Prevention and Treatment Center and Bone Health program at the University of Pittsburgh Medical Center, and colleagues evaluated 87 women, mean age 50, enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. All participants in the randomized, double-blind trial received calcium and vitamin D supplements. However, half took 35 milligrams of risedronate once a week while others took a placebo.

Chemotherapy drugs and other medical treatments for breast cancer are known to induce menopause, which can kick-start bone loss, putting survivors at risk for osteoporotic fractures, said Dr. Greenspan, an internationally respected osteoporosis researcher and professor of medicine at Pitt. This study also looked at changes in spine and hip bone mineral density, as well as evidence of bone breakdown.

Ninety-seven percent of study participants had normal or low bone mass at enrollment. At baseline, many were taking tamoxifen, a breast cancer drug aimed at estrogen-sensitive tumors that also is sometimes used as a preventive therapy by women at high risk for breast cancer.

While tamoxifen can have a positive impact on bone in postmenopausal women, a small percentage of women were taking aromatase inhibitors (also used for prevention), which can have a negative effect on bone. During the second year of the study, about half the women began taking aromatase inhibitors and stopped taking tamoxifen.

After 24 months, women in the placebo group had significant bone loss in the spine and hip that we didnt see in women taking risedronate, noted Dr. Greenspan. In fact, women taking risedronate had a bone density much higher in the spine and hip than women in the placebo group. The researchers also observed that the greatest bone loss was found in women on aromatase inhibitors. Even so, risedronate continued to be successful in preventing bone loss.

We conclude that once weekly doses of risedronate improves bone density and prevents excess bone loss in breast cancer survivors, the researchers noted.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR
3. New treatment for Osteoporosis
4. Osteoporosis in men
5. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
6. Osteoporosis Drugs: right time to take-off
7. Fluoride Found Effective in Osteoporosis
8. Cement injections linked to osteoporosis
9. Cure for osteoporosis in prostate cancer patients
10. Mutation connected to Osteoporosis
11. Osteoporosis associated with Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology: